Microsoft And 1910 Genetics Partner To Turbocharge R&D Productivity For The Pharmaceutical Industry
Microsoft News, Thursday, February 29th, 2024
Unprecedented collaboration will build the most powerful, fully integrated, AI-driven drug discovery and development platform to dramatically improve pharmaceutical research and development (R&D) productivity and bring novel therapeutics to patients faster and more cost-effectively than traditional approaches.
Microsoft and 1910 Genetics, the only biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation, announced a new five-year commercial agreement and go-to-market collaboration to harness advanced AI and next generation high-performance computing (HPC).
This is to reverse 70 years of declining pharmaceutical R&D productivity by combining 1910's massive computational and wet lab biological data, robotics-driven laboratory automation and multimodal AI models for drug discovery with Microsoft Azure Quantum Elements, a groundbreaking cloud platform purpose built at the intersection of advanced AI and HPC to accelerate scientific discovery. 1910 Genetics will offer the platform to pharmaceutical, biotechnology, government, academic, and research institutions via three partnership models: co-discovery, co-engineering, and Platform-as-a-Service (PaaS).